Comment on: Khurana et al. The Diagnosis of Neonatal Diabetes in a Mother at 25 Years of Age. Diabetes Care 2012;35:e59

We read with interest the observation by Khurana et al. (1) regarding the speculative treatment of their case of neonatal diabetes (ND) pending molecular genetic confirmation. The authors report the successful trial of a sulfonylurea in a baby diagnosed with diabetes on day 2 of life in whom an activating KCNJ11 mutation was subsequently identified. Khurana et al. suggest a controlled trial of sulfonylurea in patients with ND if genetic testing is not feasible.We would not agree with this suggested management plan for two reasons: Firstly, not all patients with ND will respond to treatment with a sulfonylurea, and secondly, the result of genetic testing for ND can be available …